In 2022, MMIT launched the inaugural Patient Access Awards to recognize manufacturers who are going above and beyond to ensure that much-needed therapies get into the hands of the patients who need them.
In this research, payer and physician stakeholders assess and rank the performance of manufacturers across a series of factors, including the manufacturer’s overall commitment to a disease, account representative support, patient and family support programs and resources, patient copay assistance, physician education, and support and HUB services.
MMIT’s Indices team fields primary research for our Oncology Index and Biologics and Injectables Index reports with our industry-leading panel of payers and physicians to assess the current and emerging trends in a variety of therapeutic areas. In this research, the payers and physician panelists evaluate the pharmaceutical manufacturers within a given therapeutic area on their performance across a series of metrics related to patient access services. The winners of the MMIT Patient Access Award are the pharmaceutical manufacturers—one per therapeutic area—who receive the highest ratings by the panelists.
The winners for Q3 2022 will be announced in December 2022 and will include manufacturers within the following therapeutic areas: HIV, narcolepsy, ulcerative colitis, Crohn’s disease, multiple myeloma, ovarian cancer and prostate cancer.
Read customer success stories on their journey to solve business challenges.
A Second-to-Market Success
Learn how a data-driven market access strategy and competitor benchmarking led to launch excellence.